BACKGROUND: Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available. PATIENTS AND METHODS: Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed. RESULTS: Median time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005). CONCLUSIONS: To our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients.
BACKGROUND: Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available. PATIENTS AND METHODS: Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed. RESULTS: Median time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005). CONCLUSIONS: To our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients.
Authors: Hyung Soon Park; Sun Young Rha; Hyo Song Kim; Woo Jin Hyung; Ji Soo Park; Hyun Cheol Chung; Sung Hoon Noh; Hei-Cheul Jeung Journal: Oncology Date: 2011-06-15 Impact factor: 2.935
Authors: D Santini; M Tampellini; B Vincenzi; T Ibrahim; C Ortega; V Virzi; N Silvestris; R Berardi; C Masini; N Calipari; D Ottaviani; V Catalano; G Badalamenti; R Giannicola; F Fabbri; O Venditti; M E Fratto; C Mazzara; T P Latiano; F Bertolini; F Petrelli; A Ottone; C Caroti; L Salvatore; A Falcone; P Giordani; R Addeo; M Aglietta; S Cascinu; S Barni; E Maiello; G Tonini Journal: Ann Oncol Date: 2012-01-04 Impact factor: 32.976
Authors: David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Gian Luca Baiocchi; Guido A Tiberio; Anna Maria Minicozzi; Paolo Morgagni; Daniele Marrelli; Lorenzo Bruno; Fausto Rosa; Alberto Marchet; Arianna Coniglio; Luca Saragoni; Marco Veltri; Fabio Pacelli; Franco Roviello; Donato Nitti; Stefano M Giulini; Giovanni De Manzoni Journal: Ann Surg Date: 2010-07 Impact factor: 12.969
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Sun Min Lim; Youn Nam Kim; Ki Hyun Park; Beodeul Kang; Hong Jae Chon; Chan Kim; Joo Hoon Kim; Sun Young Rha Journal: BMC Cancer Date: 2016-07-04 Impact factor: 4.430